| 產(chǎn)品編號(hào) | BIO0318SM |
| 英文名稱 | Anti-Factor IX & Factor X Reference Antibody (Emicizumab Biosimilar) |
| 中文名稱 | |
| 別 名 | F9 / Factor IX & Factor X / Fxa; Emicizumab |
| 抗體來源 | |
| 克隆類型 | Monoclonal |
| 克 隆 號(hào) | |
| 交叉反應(yīng) | Human |
| 產(chǎn)品應(yīng)用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 145.62 kDa |
| 檢測(cè)分子量 | |
| 性 狀 | Lyophilized |
| 亞 型 | IgG-like |
| 純化方法 | Protein A |
| 緩 沖 液 | 100 mM Pro-Ac 20mM Arg pH 5.0 |
| 保存條件 | -80°C for 2 years under sterile conditions； -20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | |
| 產(chǎn)品圖片 |
Emicizumab bound to Factor X protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Emicizumab bound in human Factor X Protein-His, and the EC50 was 2.033 nM.
Emicizumab bound to Factor IX protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Emicizumab bound in human Factor IX Protein-His, and the EC50 was 2.296 nM.
Anti-CD3 & GD2 Reference Antibody (Nivatrotamab) is 100.00%, determined by SEC-HPLC.
Anti-CD3 & GD2 Reference Antibody (Nivatrotamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
|
